RapidAI Receives FDA Clearance for Pulmonary Embolism Triage and Notification

San Mateo, Calif.-based RapidAI has received the FDA’s 510(k) clearance for its Rapid PE Triage & Notification software for identifying suspected central pulmonary embolism (PE) from computed tomography images.

The notification system uses the same approach as the company’s Rapid Workflow for Stroke, which enables stroke team members to coordinate patient care from pre-diagnosis through treatment using a mobile device or a web browser on a desktop or laptop.

The PE triage software automatically identifies a suspected embolism and delivers real-time notifications to physicians. It also features secure messaging that allows team members to stay up to date on the status of patients.

“Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” the company said.

RapidAI specializes in artificial intelligence software-enhanced clinical decision support and patient workflow for neurovascular and vascular medicine.